Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) Gross Margin (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Gross Margin for 4 consecutive years, with 94.31% as the latest value for Q3 2025.

  • On a quarterly basis, Gross Margin rose 120.0% to 94.31% in Q3 2025 year-over-year; TTM through Sep 2025 was 93.01%, a 30.0% increase, with the full-year FY2024 number at 92.27%, down 99.0% from a year prior.
  • Gross Margin was 94.31% for Q3 2025 at Orchestra BioMed Holdings, roughly flat from 94.5% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 96.22% in Q1 2023 to a low of 77.08% in Q4 2024.
  • A 4-year average of 91.73% and a median of 94.34% in 2024 define the central range for Gross Margin.
  • Biggest YoY gain for Gross Margin was 906bps in 2023; the steepest drop was -1313bps in 2023.
  • Orchestra BioMed Holdings' Gross Margin stood at 95.19% in 2022, then fell by -14bps to 82.06% in 2023, then fell by -6bps to 77.08% in 2024, then increased by 22bps to 94.31% in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Gross Margin are 94.31% (Q3 2025), 94.5% (Q2 2025), and 94.93% (Q1 2025).